Lessons learned from two decades of anticancer drugs

Research output: Contribution to journalArticlepeer-review

Authors

Colleges, School and Institutes

External organisations

  • National Center for Toxicological Research, US Food and Drug Administration
  • University of Arkansas at Little Rock

Abstract

As emerging techniques continue to impact cancer genomics, precision oncology may be implemented in anticancer drug development if firmly grounded.

Novel mechanisms and novel concepts of cancer pathogenesis, such as cancer stem cells and cancer-derived induced pluripotent stem cells, provide new opportunities to model the cancer genome and may generate new avenues for anticancer drug development.

Drug combinations naturally fit for multiple cancer pathologies and tend to be the major anticancer drug development focus.

Gene editing is being tested in humans. In the near future, it may be applied to expand knowledge of cancer genomics and facilitate novel models in anticancer development.

Details

Original languageEnglish
Pages (from-to)852-872
Number of pages21
JournalTrends in Pharmacological Sciences
Volume38
Issue number10
Early online date11 Jul 2017
Publication statusPublished - 1 Oct 2017